Oncology symposium: Immuno-oncology and next generation targets
The 4th Annual Crown Bioscience Cambridge symposium this year focuses on immuno-oncology and future advances in cancer treatment. Don’t miss out on the chance to hear from AstraZeneca, Janssen, Merus, Kymab, Cantargia, Oxford BioMedica, Crescendo Biologics, and CrownBio, as well as networking with your peers.
Immuno-oncology has provided many novel agents which are already clinically approved. With these agents modulating the host immune system rather than targeting tumour cells, evaluating immunotherapies has brought many challenges for drug developers and the need for a wide range of immunocompetent preclinical models.
This symposium will bring together oncology and immuno-oncology R&D and preclinical teams to facilitate cross discipline discussions on current techniques, models and experiences in preclinical immuno-oncology drug development, as well as discussing next generation treatments/models and how to move forward with future approaches.
Discussion topics include:
- How to assess long term anti-tumour immunotherapeutic efficacy, including combination regimen effects
- The novel targets for next generation immuno-oncology agents, including CAR-T cell therapy
- The evolution of preclinical models for improved evaluation of immunotherapeutics
This free, whole day event is most suited to researchers from pharmaceutical and biotech companies, and will take place at The Cambridge Building, Babraham Research Campus on March 15th. Attendee spaces are limited, you can reserve your seat by registering today.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.